News NICE says no to Ipsen’s kidney cancer drug NICE has issued draft guidance which rejects Ipsen's Cabometyx for NHS use in previously treated advanced renal cell carcinoma (RCC).
News Merrimack goes back to drawing board with $1bn Ipsen sell-of... Merrimack sells off Onivyde and generic cancer drug
News Ipsen/Exelixis' drug approved in EU for kidney cancer Cabometyx secures new indication in renal cell carcinoma.
Views & Analysis Ipsen: future of healthcare is digital – but some at risk of... Risk of a 'two speed' healthcare because of digital inequality
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
